CRIS Current Research Information System

LAMBERTI, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.182
NA - Nord America 2.784
EU - Europa 1.801
SA - Sud America 245
AF - Africa 223
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.242
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.736
SG - Singapore 1.447
VN - Vietnam 1.421
CN - Cina 1.335
IT - Italia 452
HK - Hong Kong 406
DE - Germania 267
SE - Svezia 235
KR - Corea 232
GB - Regno Unito 192
BR - Brasile 176
IN - India 168
NL - Olanda 128
IE - Irlanda 97
RU - Federazione Russa 88
CI - Costa d'Avorio 77
CH - Svizzera 66
FI - Finlandia 65
FR - Francia 64
TG - Togo 57
ID - Indonesia 43
JP - Giappone 43
AR - Argentina 38
BG - Bulgaria 38
JO - Giordania 32
AT - Austria 29
SC - Seychelles 29
CA - Canada 20
MX - Messico 20
NG - Nigeria 18
ZA - Sudafrica 18
BE - Belgio 14
PL - Polonia 11
BD - Bangladesh 9
ES - Italia 9
CL - Cile 8
EC - Ecuador 8
UA - Ucraina 8
EE - Estonia 7
LT - Lituania 7
MA - Marocco 7
EG - Egitto 6
PK - Pakistan 6
AU - Australia 5
LB - Libano 5
TR - Turchia 5
VE - Venezuela 5
PY - Paraguay 4
RO - Romania 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
AZ - Azerbaigian 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
HU - Ungheria 3
IL - Israele 3
IQ - Iraq 3
KW - Kuwait 3
LU - Lussemburgo 3
TN - Tunisia 3
TW - Taiwan 3
CO - Colombia 2
GE - Georgia 2
IR - Iran 2
KE - Kenya 2
KG - Kirghizistan 2
SA - Arabia Saudita 2
SN - Senegal 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BB - Barbados 1
BY - Bielorussia 1
DZ - Algeria 1
GF - Guiana Francese 1
GM - Gambi 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
HT - Haiti 1
JM - Giamaica 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
MY - Malesia 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PE - Perù 1
PH - Filippine 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SR - Suriname 1
TH - Thailandia 1
TZ - Tanzania 1
UG - Uganda 1
UY - Uruguay 1
Totale 10.242
Salva come PNG Salva come JPEG
Città #
Singapore 953
Hefei 520
Ashburn 508
Ho Chi Minh City 420
Hong Kong 402
Hanoi 314
Seoul 231
Santa Clara 224
Fairfield 190
Chandler 185
Beijing 156
Southend 141
Boardman 119
Dublin 95
Bologna 89
Princeton 79
Seattle 79
Woodbridge 78
Abidjan 77
Houston 75
Dong Ket 74
Wilmington 69
Bern 61
Los Angeles 61
Lomé 57
Cambridge 46
Bengaluru 45
Buffalo 43
Da Nang 43
Helsinki 43
Milan 40
Haiphong 39
Tokyo 39
Redondo Beach 38
Sofia 38
Dallas 37
Biên Hòa 35
New York 33
Amman 32
Jakarta 31
Quận Bình Thạnh 31
Turin 31
Munich 30
Ninh Bình 27
Ann Arbor 24
Falkenstein 24
Ha Long 24
Frankfurt am Main 22
Shanghai 22
Hyderabad 21
Thái Nguyên 21
Guangzhou 20
São Paulo 20
Berlin 19
Chicago 19
Hải Dương 19
Nuremberg 19
Vicenza 19
Redmond 18
Tongling 18
Abeokuta 17
Lappeenranta 16
Oldenburg 16
Westminster 15
Brooklyn 14
Des Moines 14
Florence 14
Nanjing 14
Rome 14
Yubileyny 14
Bắc Ninh 13
Can Tho 13
Vienna 13
Phoenix 12
Vũng Tàu 12
Amsterdam 11
Breda 11
Jinan 11
Orem 11
San Diego 11
Thành Phố Bà Rịa 11
Vinh 11
Brussels 10
Bắc Giang 10
London 10
Mexico City 10
Điện Bàn 10
Medford 9
Mülheim 9
Phủ Lý 9
Quận Phú Nhuận 9
San Francisco 9
Shenyang 9
Tianjin 9
Vĩnh Tường 9
Wuhan 9
Chennai 8
Lấp Vò 8
Nam Định 8
Poplar 8
Totale 6.738
Salva come PNG Salva come JPEG
Nome #
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study 871
Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option? 204
A phase II, open-label, single arm, trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale 201
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) 171
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience 167
Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review 164
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma 161
Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors 160
Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC 158
Concordance between RTOG and EORTC prognostic criteria in low-grade gliomas 156
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? 152
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12CMutant Non-Small Cell Lung Cancer 147
The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy? 145
Treatment of advanced gastro‐entero‐pancreatic neuro‐ endocrine tumors: A systematic review and network meta‐analysis of phase iii randomized controlled trials 144
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 138
[68Ga]Ga-DOTANOC Uptake at Pancreatic Head/Uncinate Process: Is It a Persistent Diagnostic Pitfall Over Time? 137
Real-Life Use of [68Ga]Ga-DOTANOC PET/CT in Confirmed and Suspected NETs from a Prospective 5-Year Electronic Archive at an ENETS Center of Excellence: More Than 2000 Scans in More Than 1500 Patients 135
New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event 131
Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors 127
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors 126
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 126
Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor 121
Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer 121
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers with Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels 120
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 120
Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease 119
An Update on Appendiceal Neuroendocrine Tumors 118
Appendiceal goblet cell carcinoma has marginal advantages from perioperative chemotherapy: a population-based study with an entropy balancing analysis 118
Metachronous solitary metastasis to the thyroid gland from squamous cell carcinoma of the lung: a case report and literature review 117
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution 117
Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report 116
Multimodal strategy in localized merkel cell carcinoma: Where are we and where are we heading? 116
The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers 112
Landscape and future perspectives of immunotherapy in neuroendocrine neoplasia 112
Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study 107
The role of clinical and molecular factors in low-grade gliomas: What is their impact on survival? 105
Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort 104
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 103
Therapeutic options in lung neuroendocrine tumors: between established concepts and new hopes 102
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC 101
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC 101
Immunobiology of thymic epithelial tumors: Implications for immunotherapy with immune checkpoint inhibitors 101
Angioside: The role of Angiogenesis and Hypoxia in Lung Neuroendocrine Tumours According to Primary Tumour Location in Left or Right Parenchyma 100
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors 100
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) 99
[177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective 99
Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study 98
The functioning side of the pancreas: a review on insulinomas 96
Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study 96
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer 95
Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges 95
Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET) 91
Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors 91
Peptide receptor radionuclide therapy for GEP-NET: consolidated knowledge and innovative applications 91
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database 89
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study 89
High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients 88
Prophylactic cholecystectomy is not mandatory in patients candidate to the resection for small intestine neuroendocrine neoplasms: a propensity score-matched and cost-minimization analysis 85
Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives 84
An overview on molecular characterization of thymic tumors: Old and new targets for clinical advances 83
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study 82
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC 82
Current Management and Predictive Factors of Lymph Node Metastasis of Appendix Neuroendocrine Tumors: A National Study From the French Group of Endocrine Tumors (GTE) 80
Radiomics in advanced gastroenteropancreatic neuroendocrine neoplasms: Identifying responders to somatostatin analogs 79
The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis 79
Lymph node ratio predicts efficacy of postoperative radiation therapy in nonmetastatic Merkel cell carcinoma: A population-based analysis 79
Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab? 76
Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study 75
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer 74
β1600 Q.Clear Digital Reconstruction of [68Ga]Ga-DOTANOC PET/CT Improves Image Quality in NET Patients 68
Cutaneous Scapular Lesion in an Elderly Woman 67
Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study 66
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer 65
Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management 61
Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities 60
Gastric neuroendocrine neoplasms 59
Challenges and future perspectives for the use of temozolomide in the treatment of SCLC 58
Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis 58
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma 56
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer 55
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer 55
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 54
BRAF V600E-mutated large cell neuroendocrine carcinoma responding to targeted therapy: A case report and review of the literature 54
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status 54
Non-small-cell lung cancer: how to manage RET-positive disease 52
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer 51
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions 50
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy 49
Should we lose hope in adjuvant therapy for neuroendocrine tumors?—In response to: Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit 48
Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) (British Journal of Cancer, (2020), 123, 1, (26-32), 10.1038/s41416-020-0845-3) 46
Role of [18F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors 46
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC 45
Non-small-cell lung cancer: how to manage EGFR-mutated disease 43
ROS1-rearranged Non–small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS) 43
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: Rationale and clinical implication 41
Antibody–drug conjugates for lung cancer in the era of personalized oncology 41
Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities 40
Title: Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer 39
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC 39
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib 39
Totale 10.249
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.204
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.204
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021369 0 0 0 0 0 25 28 36 58 40 19 163
2021/2022706 12 11 28 30 77 34 15 62 47 63 222 105
2022/20231.229 79 129 50 97 80 87 59 92 244 70 109 133
2023/2024490 36 60 34 40 37 110 24 67 14 32 20 16
2024/20252.682 114 250 264 192 360 139 212 104 37 179 231 600
2025/20264.493 1.602 890 594 556 576 275 0 0 0 0 0 0
Totale 10.577